Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - amikacin sulfate 325 mg/ml equivalent to 250 mg/ml amikacin - solution for injection - 500 mg/2ml - active: amikacin sulfate 325 mg/ml equivalent to 250 mg/ml amikacin excipient: sodium citrate dihydrate sodium hydroxide sodium metabisulfite sulfuric acid water for injection

Estados Unidos - inglês - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin 250 mg in 1 ml - amikacin sulfate injection usp is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia  coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species, and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection usp to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. aminoglycosides, including amikacin sulfate injection usp are not indicated in uncomplicated initial episodes of urin

Estados Unidos - inglês - NLM (National Library of Medicine)

fresenius kabi usa, llc - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin 250 mg in 1 ml - amikacin sulfate injection, usp is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella species, enterobacter species, serratia species, and acinetobacter species. to reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of hypersensitivity to amikacin is a contraindication for its use. a history of hypersensitivity or serious toxic react

Estados Unidos - inglês - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin 250 mg in 1 ml - amikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species, and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. aminoglycosides, including amikacin sulfate injection are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. amikacin may be considered as initial therapy in suspected gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. clinical trials demonstrated that amikacin was effective in infections caused by gentamicin- and/or tobramycin-resistant strains of gram-negative organisms, particularly proteus rettgeri , providencia stuartii , serratia marcescens , and pseudomonas aeruginosa . the decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the warnings box above. amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/gram-negative infections. in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. to reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of hypersensitivity to amikacin is a contraindication for its use. a history of hypersensitivity or serious toxic reactions to aminoglycosides may contraindicate the use of any other aminoglycoside because of the known cross-sensitivities of patients to drugs in this class.

Estados Unidos - inglês - NLM (National Library of Medicine)

sagent pharmaceuticals - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin 250 mg in 1 ml - amikacin sulfate injection, usp is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species, and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection, usp to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. aminoglycosides, including amikacin sulfate injection, usp are not indicated in uncomplicated initial episodes of uri

Estados Unidos - inglês - NLM (National Library of Medicine)

teva parenteral medicines, inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including postvascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. aminoglycosides, including amikacin sulfate injection, are not indicated in uncomplicated initial episodes of urinary tract infec

Estados Unidos - inglês - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin sulfate injection usp is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia  coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species, and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection usp to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. aminoglycosides, including amikacin sulfate injection usp are not indicated in uncomplicated initial episodes of urin

Estados Unidos - inglês - NLM (National Library of Medicine)

teva parenteral medicines, inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin 500 mg in 2 ml

Canadá - inglês - Health Canada

sandoz canada incorporated - amikacin (amikacin sulfate) - liquid - 250mg - amikacin (amikacin sulfate) 250mg - aminoglycosides

Canadá - inglês - Health Canada

marcan pharmaceuticals inc - amikacin (amikacin sulfate) - solution - 500mg - amikacin (amikacin sulfate) 500mg - aminoglycosides